Navigation Links
Perrigo Confirms Filing For Generic Version Of Acanya
Date:11/20/2013

ALLEGAN, Mich., Nov. 20, 2013 /PRNewswire/ -- Perrigo Company (NYSE: PRGO;TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) for Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% and has notified Dow Pharmasciences, the owner of the New Drug Application (NDA) of its filing.

(Logo:  http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

On November 15, 2013, Dow Pharmasciences and Valeant Pharmaceuticals filed suit against Perrigo in the United States District Court for the District of New Jersey, alleging patent infringement. This action formally initiates the process under the Hatch-Waxman Act. 

Acanya® Gel is indicated for the topical treatment of acne vulgaris in patients 12 years or older. Annual sales were approximately $122 million annually, as measured by Symphony Health Solutions.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This filing is another example of our investment in extended topical product development. As always, Perrigo is committed to making quality healthcare more affordable for our customers."                  

From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Company has grown to become a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico, the United Kingdom, India, China and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2012, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 


'/>"/>
SOURCE Perrigo Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
2. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
3. Perrigo Company to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference
4. Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules
5. Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream
6. Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension
7. Perrigo Company To Present At The William Blair Growth Stock Conference
8. Perrigo Receives FDA Approval And Commences Launch Of Clobetasol Propionate Shampoo, 0.05%
9. Perrigo Company Announces Quarterly Dividend
10. Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference
11. Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... CHICAGO, Ill. , March 23, 2017 ... dancer and Emmy Award-winning choreographer Julianne Hough ... campaign called "Get in the Know about ME in ... is dedicated to inspiring women to learn about and ... 10 women, 1 and to address their symptoms ...
(Date:3/23/2017)... 2017 The global dermatology devices ... billion by 2025, according to a new report by Grand ... a faster rate due to rising concern amongst people regarding ... of esthetic procedures used for treating hair - and skin-related ... considered as the highest revenue generators for the market. ...
(Date:3/22/2017)... , March 23, 2017 ReportsnReports.com ... a latest research report. The global vagus nerve stimulation ... of surgeons focus toward minimally invasive VNS procedures. Few ... to few developed countries having high standards of healthcare ... ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... ... of God. “A Respectful Response To Atheist Manifesto” is the creation of published ... his wife, Nancy, for sixty years. He holds graduate degrees from Kent State ...
(Date:3/23/2017)... ... 23, 2017 , ... “More Corruption”: a simple and strong explanation of the God’s love. ... rulers of Heaven was asked by God to write a book about Him. , She ... because I kept my commitment to the Lord God. They have not walked in my ...
(Date:3/22/2017)... Australia (PRWEB) , ... March 23, 2017 , ... Death ... a nurse by profession, author Joy Nugent was inspired to write the book titled ... came from her inward desire to make sense of what she was experiencing at ...
(Date:3/22/2017)... ... March 23, 2017 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had won the ... place at the Suntec Singapore International Exhibition & Convention Centre, Singapore. The award ...
(Date:3/22/2017)... San Jose, CA (PRWEB) , ... March 22, ... ... of San Jose, Santa Cruz and Milpitas with a robust, ongoing community enrichment ... Supportive Housing (FSH), a nonprofit organization which has provided for the critical needs ...
Breaking Medicine News(10 mins):